• JAYARAMA REDDY Department of Botany, St. Joseph College, Bengaluru, Karnataka, India.


Objective: Insulin is used to manage diabetes mellitus by subcutaneous injections regulary, that has become a part of patients life and is distressing for patients. Hence, we anticipate to get rid of the usage of subcutaneous injections completely from the medicine world and would make the diabetic people to say as “farewell to painful injections.”

Methods: Virtual screening method (for selection of carriers), Toxtree tool (for toxicity evaluation of carriers), and discovery studio tool (for pharmacophore designing, absorption, distribution, metabolism, excretion, and toxicity [ADMET] analysis, designing oral insulin conjugates (OICs), and interaction studies between insulin receptor and OICs) were used for proposed study.

Results: We have screened 14 competent drug delivering molecules (DDMs) from seven chemical compound databases. The ADMET and pharmacophoric properties of DDMs were analyzed by drug-informatics’ tools. Consequently, the DDMs were mono, di, and poly conjugated by covalent bonding with various binding sites of monomeric and hexameric form of human insulin and insulin-lispro (Humalog®) individually; and novel OICs were generated. Its binding efficiency and biological activity with insulin-receptor were determined.

Conclusion: Inulin and Vitamin-B1 are the novel, safe, and proficient carriers for oral delivery of insulin. Insulin lispro is the remarkable option for oral delivery than other insulin forms.

Keywords: Oral insulin, Diabetes, Drug delivery, Insulin tablets


1. Cockburn IM, Henderson RM. Scale and scope in drug development: Unpacking the advantages of size in pharmaceutical research. J Health Econ 2001;20:1033-57.
2. Gowthamarajan K, Kulkarni GT. Oral insulin-fact or fiction? Resonance 2003;8:38-46.
3. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in Type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Technol Ther 2002;4:459-66.
4. Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst 1991;8:331-94.
5. Lee S, Kim K, Kumar TS, Lee J, Kim SK, Lee DY, et al. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates. Bioconjug Chem 2005;16:615-20.
6. Macedo A, Filipe P, Thomé NG, Vieira J, Oliveira C, Teodósio C, et al. A brief overview of the oral delivery of insulin as an alternative to the parenteral delivery. Curr Mol Med 2020;20:134-43.
7. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. Chem Med Chem 2007;2:1717-21.
8. Murray?Rust J, McLeod AN, Blundell TL, Wood SP. Structure and evolution of insulins: Implications for receptor binding. Bioessays 1992;14:325-31.
9. Jeffrey PD. The self-association of zinc-free bovine insulin. Four model patterns and their significance. Biol Chem Hoppe Seyler 1990;371:1165-74.
10. Uchio T, Baudyš M, Liu F, Song SC, Kim SW. Site-specific insulin conjugates with enhanced stability and extended action profile. Adv Drug Deliv Rev 1999;35:289-306.
11. Oprea TI, Davis AM, Teague SJ, Leeson PD. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001;41:1308-15.
12. Zhu X, Ji J, Huang D, Zhu Y, Tang C, Yang X, et al. Discovery, synthesis and evaluation of novel cholesterol absorption inhibitors. Chem Biol Drug Des 2012;80:426-33.
13. Rybacka A, Rudén C, Andersson PL. On the use of in silico tools for prioritising toxicity testing of the low?volume industrial chemicals in REACH. Basic Clin Pharmacol Toxicol 2014;115:77-87.
14. Ravi L, Ragunathan A. Potential drug targets for Aloin and microdontin: An in-silico analysis. Asian J Pharm Clin Res 2016;9:194-6.
15. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res 2016;44:D1202-13.
16. Kavimandan NJ, Losi E, Wilson JJ, Brodbelt JS, Peppas NA. Synthesis and characterization of insulin-transferrin conjugates. Bioconjug Chem 2006;17:1376-84.
17. Hinds K, Koh JJ, Joss L, Liu F, Baudyš M, Kim SW. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjug Chem 2000;11:195-201.
18. Deegan KL, Jones KM, Zuleta C, Ramirez-Zea M, Lildballe DL, Nexo E, et al. Breast milk Vitamin B-12 concentrations in Guatemalan women are correlated with maternal but not infant Vitamin B-12 status at 12 months postpartum. J Nutr 2012;142:112-6.
19. Yan L, Chen W, Zhu X, Huang L, Wang Z, Zhu G, et al. Folic acid conjugated self-assembled layered double hydroxide nanoparticles for high-efficacy-targeted drug delivery. Chem Commun 2013;49:10938-40.
20. Martin G, Finberg L. Propylene glycol: A potentially toxic vehicle in liquid dosage form. J Pediatr 1970;77:877-8.
21. Runge MB, Wang H, Spinner RJ, Windebank AJ, Yaszemski MJ. Reformulating polycaprolactone fumarate to eliminate toxic diethylene glycol: Effects of polymeric branching and autoclave sterilization on material properties. Acta Biomater 2012;8:133-43.
22. Inchem I. Chemical safety information from intergovernmental organizations. Can Cent 2011.
95 Views | 121 Downloads
How to Cite
REDDY, J. “COMPUTATIONAL DESIGN OF NOVEL ORAL INSULIN CONJUGATES FOR THE DEVELOPMENT OF SOLID ORAL INSULIN DOSAGE FORMS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 5, May 2020, pp. 141-5, doi:10.22159/ajpcr.2020.v13i5.37308.
Original Article(s)